43.57
+0.96(+2.25%)
Currency In USD
| Previous Close | 42.61 |
| Open | 42.51 |
| Day High | 44.5 |
| Day Low | 41.55 |
| 52-Week High | 45.94 |
| 52-Week Low | 14.8 |
| Volume | 371,719 |
| Average Volume | 1.03M |
| Market Cap | 3.27B |
| PE | -21.25 |
| EPS | -2.05 |
| Moving Average 50 Days | 41.36 |
| Moving Average 200 Days | 30.03 |
| Change | 0.96 |
CG Oncology Announces New Board Member and Board Transition
GlobeNewswire Inc.
Nov 26, 2025 12:00 PM GMT
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing an
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patientsIRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
GlobeNewswire Inc.
Sep 05, 2025 11:00 AM GMT
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month r